TABLE 4

Nonsusceptible rates of most common serogroups/types observed among noninvasive S. pneumoniae isolates collected during 2009 to 2012 in the United States

Serogroup/type% nonsusceptibilitya by yr
PenicillinCeftriaxoneClindamycinErythromycin
2009201020112012200920102011201220092010201120122009201020112012
PCV732.0 (52.0)28.9 (52.6)19.1 (55.3)16.2 (51.4)28.021.117.021.632.031.623.418.952.052.659.648.6
    19F26.7 (46.7)33.3 (50.0)25.8 (45.2)20.0 (60.0)20.025.022.620.040.037.529.024.046.750.041.940.0
Additional PCV1334.9 (52.3)33.6 (50.0)42.6 (58.6)35.7 (51.9)26.722.829.231.434.933.244.838.145.649.660.252.4
    19A66.8 (89.8)61.5 (86.2)78.9 (96.3)74.7 (91.2)50.041.352.263.764.856.973.370.373.980.791.986.8
    30.0 (0.0)0.0 (0.0)0.0 (2.4)0.0 (6.2)0.00.00.00.06.05.015.512.56.08.314.314.1
    7F0.0 (9.5)0.0 (0.0)0.0 (8.3)0.0 (0.0)0.00.00.00.00.00.00.07.74.80.08.37.7
PPSV23-nonPCV130.7 (10.4)0.0 (8.1)1.3 (15.7)0.5 (13.2)2.20.01.71.51.53.55.73.626.122.134.132.5
    11A/11D0.0 (8.8)0.0 (2.4)0.0 (8.2)2.3 (6.8)2.90.02.02.30.00.02.04.535.319.534.727.3
    22A/22F0.0 (6.5)0.0 (0.0)4.1 (14.3)0.0 (2.9)3.20.02.02.96.52.812.25.717.916.736.720.0
    15B/15C0.0 (33.3)0.0 (33.3)2.1 (44.7)0.0 (36.2)0.00.02.10.00.05.66.42.146.738.961.753.2
    17F0.0 (7.1)0.0 (0.0)0.0 (0.0)0.0 (9.1)0.00.00.09.10.00.00.00.028.618.220.09.1
    10A7.7 (15.4)0.0 (0.0)0.0 (5.0)0.0 (0.0)7.70.00.00.00.00.00.09.17.70.010.09.1
    9N/9L0.0 (0.0)0.0 (4.5)0.0 (7.7)0.0 (4.8)0.00.00.00.00.013.63.84.80.018.23.89.5
    33F/33A/370.0 (0.0)0.0 (0.0)0.0 (7.1)0.0 (8.3)0.00.07.10.00.00.014.30.071.450.057.191.7
Nonvaccineb1.9 (44.0)0.4 (47.6)0.5 (55.0)0.3 (52.8)1.90.01.60.915.518.116.914.533.337.642.937.0
    6C/6D0.0 (60.0)0.0 (42.5)0.0 (59.4)0.0 (55.6)0.00.03.10.02.22.53.15.653.340.056.250.0
    23A0.0 (45.2)0.0 (75.0)0.0 (70.4)0.0 (71.7)0.00.00.00.06.515.616.713.09.725.018.526.1
    15A/15F0.0 (76.7)0.0 (97.5)0.0 (90.9)0.0 (88.2)0.00.00.00.080.092.595.588.286.795.097.794.1
    23B0.0 (27.3)0.0 (27.3)2.7 (32.4)0.0 (44.2)0.00.02.70.00.04.55.49.313.64.527.011.6
    35B5.0 (80.0)2.2 (91.1)1.4 (95.9)1.6 (91.8)5.00.02.74.95.04.44.11.640.060.062.254.1
    16F6.7 (13.3)0.0 (0.0)0.0 (9.1)0.0 (6.2)6.70.04.50.00.00.09.16.20.013.09.16.2
    317.7 (7.7)0.0 (0.0)0.0 (0.0)0.0 (0.0)7.70.00.00.015.40.00.05.023.127.826.125.0
    35F/47F0.0 (0.0)0.0 (10.0)0.0 (0.0)0.0 (0.0)0.00.00.00.00.00.00.00.00.010.027.312.5
    340.0 (0.0)0.0 (0.0)0.0 (8.3)0.0 (9.1)0.00.00.00.00.011.80.00.00.011.88.318.2
    7C/7B/400.0 (20.0)0.0 (0.0)0.0 (10.0)0.0 (0.0)0.00.00.00.020.00.00.00.020.00.00.00.0
Nontypeable0.0 (23.1)7.7 (61.5)0.0 (40.9)0.0 (13.3)0.00.00.00.015.430.813.60.023.153.840.933.3
All13.3 (38.3)11.6 (38.8)15.0 (46.3)10.3 (41.3)10.77.710.99.718.919.823.518.035.738.146.640.1
  • a Data represent percentages of nonsusceptible isolates according to the susceptible parenteral (≤2 μg/ml) (for nonmenigitis patients) and oral (≤0.06 μg/ml) (in parentheses) penicillin breakpoints for ceftriaxone (≤1 μg/ml), clindamycin (≤0.25 μg/ml), and erythromycin (≤0.25 μg/ml) published in the CLSI M100-S24 document.

  • b “Nonvaccine” indicates those strains not present in the three vaccines available in the United States.